Search NASA⌕ Search

Engineering topics

Joshua Ong

Publications and source records attributed to Joshua Ong.

Spaceflight Associated Neuro-Ocular Syndrome (Sans): Proposed Pathogenesis, Terrestrial Analogs, and Emerging Countermeasures

Spaceflight Associated Neuro-ocular Syndrome (SANS) refers to a distinct constellation of ocular, neurological, and neuroimaging findings observed in astronauts during and following long duration spaceflight. These ocular findings, to include optic disc edema, posterior globe flattening, chorioretinal folds, and hyperopic shifts, were first described by NASA in 2011. SANS is a potential risk to astronaut health and will likely require mitigation prior to planetary travel with prolonged exposures to microgravity. While the exact pathogenesis of SANS is not completely understood, several hypotheses have been proposed to explain this neuro-ocular phenomenon. In this paper, we briefly discuss the current hypotheses and contributing factors underlying SANS pathophysiology as well as analogs utilized to study SANS on Earth. We also review emerging potential countermeasures for SANS including lower body negative pressure, nutritional supplementation, and translaminar pressure gradient modulation. Ongoing investigation within these fields will likely be instrumental in preparing and protecting astronaut vision for future spaceflight missions including deep space exploration.

Astronauts↗

Optimizing Screening for Preventable Blindness With Head-Mounted Visual Assessment Technology

Age-related macular degeneration (AMD) is a leading cause of blindness and is diagnosed as early-stage or late-stage. Early-stage AMD is usually asymptomatic and entails pigmentary changes of the retina (Ayoub & Patel, 2009). As the disorder progresses, there are atrophic or neovascular changes that distort vision, especially the central visual field (Ayoub & Patel, 2009). There are several genetic and non-genetic risk factors for AMD and no proven therapy to slow or reverse late-stage atrophic AMD, while anti-VEGF has effectively treated late-stage neovascular AMD. Several genes of interest have also been investigated thoroughly thus far in their connection to AMD and the CFH and ARMS2 genes have shown promise in understanding the genetic basis of the disorder (Awh et al., 2013). There are other epigenetic and environmental factors as well including smoking and low antioxidant levels (Cano et al., 2010). Ongoing investigations include antioxidant supplementation and a smoking cessation regimen to reverse early-stage AMD (Cano et al., 2010). Progress in treating AMD as a disorder across its varied stages requires newer therapeutics along with a more detailed understanding of the genetic and cellular pathways of pathophysiology is needed to better counter this prevalent disorder of the eye.

age-related macular degeneration↗